StockData

Rani Therapeutics vs TherapeuticsMD

RANI and TXMD side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How RANI and TXMD compare

Rani Therapeutics is the larger company, worth 3.6 times as much as TherapeuticsMD ($75.3M against $20.9M).

Rani Therapeutics grew revenue faster over the last twelve months (306% versus 27.8% for TherapeuticsMD).

TherapeuticsMD keeps more of each dollar of sales as profit, with a net margin of −6.6% compared with −618% at Rani Therapeutics.

TherapeuticsMD scores higher on the StockData Score (12 against 3 for Rani Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricRANITXMD
Size and price
Market cap$75.3M$20.9M
Share price$0.540$1.81
Change, 1 year−72.0%11.7%
Change, 5 years−98.2%−93.8%
Beta (5Y)1.600.44
Employees691
StockData Score
Total score312 (better)
Valuation score13 (better)
Growth score11
Performance score03 (better)
Health score15 (better)
Dividend score00
Valuation
P/S15.4×6.4× (better)
P/B1.9×0.8× (better)
FCF yield−27.0%–
Fair value$0.388$2.56
Margin of safety−39.1%29.4% (better)
Growth
Revenue growth (TTM)306% (better)27.8%
Revenue growth, 5Y average28.7% (better)−45.8%
Profitability
Operating margin−676%−121% (better)
Net margin−618%−6.6% (better)
FCF margin−417%–
Return on equity−179%−0.80% (better)
Return on invested capital−145%−15.9% (better)
Financial health
Debt / equity–0.00
Interest coverage−28.2×–
Current ratio5.31 (better)3.22
Altman Z-score−0.67 (better)−34.22
Piotroski F-score56 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions32.7%31.7%
Held by insiders30.6%1.6%
Insider net buying, 12 months$49.7K (better)$14.0K
Short interest, % of float8.5%0.27%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.